Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment

Authors

C Correll
J Kane
Leslie Citrome, New York Medical CollegeFollow

DOI

10.4088/JCP.tv17016ah4c

Journal Title

The Journal of Clinical Psychiatry

First Page

1136

Last Page

1147

Document Type

Article

Publication Date

9-1-2017

Department

Psychiatry and Behavioral Sciences

Keywords

Tardive Dyskinesia, Antipsychotic Agents, Long Term Adverse Effects, Medication Therapy Management, Neuromuscular Agents

Disciplines

Clinical Psychology | Medical Pharmacology | Medicine and Health Sciences | Psychiatry

Abstract

Tardive dyskinesia (TD) is a disorder characterized by involuntary movements, typically of the orofacial muscles and also of the extremities and other muscle groups. The condition is associated with exposure to dopamine receptor blocking agents, including antipsychotics. Because the indications and off-label uses for these agents have expanded over the last 2 decades, a larger number of patients are receiving antipsychotic medications than in the past. While evidence suggests that patients being treated with second-generation antipsychotics have less risk for developing TD than those treated with first-generation antipsychotics, the decreased risk is not as great as was originally expected. In addition, patients with chronic psychiatric conditions often require long-term use of antipsychotics, putting them at risk for TD. This article addresses the prevalence, risk factors, and prevention of TD; assessment strategies including diagnostic criteria and rating scales; and evidence for TD treatments, including 2 newly approved medications: deutetrabenazine and valbenazine. .

Recommended Citation

Correll, C., Kane, J., & Citrome, L. (2017). Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment. The Journal of Clinical Psychiatry, 78 (8), 1136-1147. https://doi.org/10.4088/JCP.tv17016ah4c